Akums reports Q1 FY26 PAT at Rs. 65 Cr

During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals

Cupid Q1 FY26 PAT jumps 82% at Rs. 15 Cr

Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25

Suraksha Diagnostic reports Q1 FY26 PAT higher by 20% at Rs. 9.1 Cr

Metropolis Healthcare reports Q1 FY26 PAT higher by 19% at Rs. 45 Cr

Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr

Our specialty chemical businesses have continued to perform strongly, growing double digit YoY

Maziar Mike Doustdar appointed President and CEO of Novo Nordisk

Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit

Rise of Bio-based Chemicals: Hype or Game-Changer?: Dr. Sangeeta Srivastava, Executive Director, Godavari Biorefineries

The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production

GSK forges $12 billion alliance with Hengrui Pharma

GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr

During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D

Biogen to invest $2 billion to expand manufacturing capability in North Carolina

Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date